Catalyst Pharmaceuticals, Inc.

CPRX

US14888U1016

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.89 ^USD	+1.43%		-1.59%	-11.42%

Apr. 10	Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	MT
Apr. 04	Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	CI

Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 05:16 pm EST

Catalyst Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 398.2 million compared to USD 214.2 million a year ago. Net income was USD 71.41 million compared to USD 83.08 million a year ago.

Basic earnings per share from continuing operations was USD 0.67 compared to USD 0.8 a year ago. Diluted earnings per share from continuing operations was USD 0.63 compared to USD 0.75 a year ago.

Latest news about Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	Apr. 10	MT
Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	Apr. 03	CI
Certain Restricted Stock Units of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	Apr. 03	CI
Certain Common Stock of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	Apr. 03	CI
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	Mar. 28	MT
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target	Mar. 14	MT
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States	Mar. 14	DJ
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy	Mar. 13	MT
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	Mar. 13	CI
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM	Mar. 12
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals	Mar. 07	MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23	Mar. 07	MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating	Mar. 01	MT
Transcript : Catalyst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	Feb. 29	CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Catalyst Pharmaceuticals Seeks Acquisitions	Jan. 10	CI
Catalyst Pharmaceuticals Raises $140.1 Million From Share Offering	Jan. 09	MT
Top Stories at Midday: December US Nonfarm Payrolls Rise; ISM US Services Index Falls; CVS Names Finance Chief; Tesla to Recall Vehicles in China; Catalyst Prices Stock Offering	Jan. 05	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	Jan. 05	MT
Catalyst Pharmaceuticals Prices $150 Million Share Offering	Jan. 05	MT
Catalyst Pharmaceuticals Unveils $150 Million Equity Offering -- Shares Slump After Hours	Jan. 04	MT
Oppenheimer Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $30 Price Target	Dec. 21	MT
Dydo Group Unit Files New Drug Application for Autoimmune Disease Treatment Candidate	Dec. 19	MT

Chart Catalyst Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Catalyst Pharmaceuticals, Inc: Optimistic scenario

March 06, 2023 at 10:44 am EST

More Strategies

Ratings for Catalyst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.89 USD

Average target price

26.71 USD

Spread / Average Target

+79.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CATALYST PHARMACEUTICALS, INC.	-11.42%	1.76B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals